Related references
Note: Only part of the references are listed.Bicyclic Picomolar OGA Inhibitors Enable Chemoproteomic Mapping of Its Endogenous Post-translational Modifications
Manuel Gonzalez-Cuesta et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2022)
Pathological mechanisms and therapeutic strategies for Alzheimer's disease
Yaojun Ju et al.
NEURAL REGENERATION RESEARCH (2022)
Mechanistic roles for altered O-GlcNAcylation in neurodegenerative disorders
Aaron T. Balana et al.
BIOCHEMICAL JOURNAL (2021)
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature
Jose M. Bartolome-Nebreda et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
O-GlcNAcase: Emerging Mechanism, Substrate Recognition and Small-Molecule Inhibitors
Ahmed A. Elbatrawy et al.
CHEMMEDCHEM (2020)
Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes andC-5a-Substituted Derivatives of 4-epi-Isofagomine
Patrick Weber et al.
MOLECULES (2020)
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies
Harold G. Selnick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections
Burcu Isler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Tau Biology, Tauopathy, Traumatic Brain Injury, and Diagnostic Challenges
Rudy J. Castellani et al.
JOURNAL OF ALZHEIMERS DISEASE (2019)
Potent GH20 N-Acetyl-β-D-hexosaminidase Inhibitors: N-Substituted 3-acetamido-4-amino-5-hydroxymethyl-cyclopentanediols
Patrick Weber et al.
MOLECULES (2018)
Phage Therapy for a MultidrugResistant Acinetobacter baumannii Craniectomy Site Infection
Stephanie LaVergne et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
The cost of antimicrobial resistance
Ursula Hofer
NATURE REVIEWS MICROBIOLOGY (2018)
Untangling the Tauopathy for Alzheimer's disease and parkinsonism
Hui-Yun Chang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2018)
Inhibition of O-GlcNAcase leads to elevation of O-GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice
Nicholas B. Hastings et al.
MOLECULAR NEURODEGENERATION (2017)
Structural and functional insight into human O-GlcNAcase
Christian Roth et al.
NATURE CHEMICAL BIOLOGY (2017)
A new type of pharmacological chaperone for GM1-gangliosidosis related human lysosomal β-galactosidase: N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols
Michael Schalli et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Tau and neurodegenerative disease: the story so far
Khalid Iqbal et al.
NATURE REVIEWS NEUROLOGY (2016)
Expression of human β-N-acetylhexosaminidase B in yeast eases the search for selective inhibitors
Jana Krejzova et al.
ENZYME AND MICROBIAL TECHNOLOGY (2016)
Improvement of the BALB/c-3T3 cell transformation assay: a tool for investigating cancer mechanisms and therapies
Doerte Poburski et al.
SCIENTIFIC REPORTS (2016)
O-GlcNAcase: Promiscuous Hexosaminidase or Key Regulator of O-GlcNAc Signaling?
Jana Alonso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice
Scott A. Yuzwa et al.
MOLECULAR NEURODEGENERATION (2014)
The carbohydrate-active enzymes database (CAZy) in 2013
Vincent Lombard et al.
NUCLEIC ACIDS RESEARCH (2014)
Comparative Biochemistry of GH3, GH20 and GH84 β-N-acetyl-D-hexosaminidases and Recent Progress in Selective Inhibitor Discovery
Tian Liu et al.
CURRENT DRUG TARGETS (2012)
Insights into O-Linked N-Acetylglucosamine (O-GlcNAc) Processing and Dynamics through Kinetic Analysis of O-GlcNAc Transferase and O-GlcNAcase Activity on Protein Substrates
David L. Shen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Cell-Penetrant, Nanomolar O-GlcNAcase Inhibitors Selective against Lysosomal Hexosaminidases
Helge C. Dorfmueller et al.
CHEMISTRY & BIOLOGY (2010)
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Scott A. Yuzwa et al.
NATURE CHEMICAL BIOLOGY (2008)
Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells
Walter M. A. Westerink et al.
TOXICOLOGY IN VITRO (2007)
Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells
Walter M. A. Westerink et al.
TOXICOLOGY IN VITRO (2007)
Fluorescent glycosidase inhibiting 1,5-dideoxy-1,5-iminoalditols
P Greimel et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
O-GlcNAcase uses substrate-assisted catalysis -: Kinetic analysis and development of highly selective mechanism-inspired inhibitors
MS Macauley et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Reduction of azides to amines or amides with zinc and ammonium chloride as reducing agent
WQ Lin et al.
SYNTHETIC COMMUNICATIONS (2002)
Distribution and in-vitro transfer of tetracycline resistance determinants in clinical and aquatic Acinetobacter strains
L Guardabassi et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2000)
Share Paper
